Holen Sie sich die Stockscreener-App
199.59
0.93%
1.84
Schlusskurs vom Vortag:
$197.75
Offen:
$200.05
24-Stunden-Volumen:
238.55K
Relative Volume:
0.34
Marktkapitalisierung:
$10.63B
Einnahmen:
$4.08B
Nettoeinkommen (Verlust:
$431.79M
KGV:
21.17
EPS:
9.43
Netto-Cashflow:
$486.92M
1W Leistung:
+6.22%
1M Leistung:
+9.59%
6M Leistung:
-8.11%
1J Leistung:
+2.51%
1-Tages-Spanne:
$198.23
$202.56
1-Wochen-Bereich:
$186.62
$202.87
52-Wochen-Spanne:
$176.48
$275.00
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
199.59 | 10.63B | 4.08B | 431.79M | 486.92M | 9.43 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Mudita Advisors LLP Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles Schwab Investment Management Inc. Purchases 32,311 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
While shareholders of Charles River Laboratories International (NYSE:CRL) are in the red over the last three years, underlying earnings have actually grown - Simply Wall St
Charles River labs accused of exploiting loophole to move monkeys through Canada - Montreal Gazette
Charles River Labs shares target cut, rating held on Q2 results - Investing.com Canada
Charles River Laboratories International Inc (CRL) Stock Price U - GuruFocus.com
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Citigroup Inc. - MarketBeat
Horizon Kinetics Asset Management LLC Sells 45,619 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Reduce" from Analysts - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 63,588 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Large Molecule Bioanalytical Technologies Market Research Explores Drivers And Growth Report 2033 - WhaTech
Lathrop Investment Management Corp Cuts Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
King Luther Capital Management Corp Sells 252,657 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Brown Capital Management LLC Sells 13,542 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Medical Device Testing Services Market Growth, Size, Trends, - openPR
Charles River Laboratories To Present At Jefferies London Healthcare Conference; Webcast At 9:00 AM - Nasdaq
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Premier Fund Managers Ltd - MarketBeat
Charles River Labs closes several locations, 1,300+ jobs cut in cost saving initiative - MSN
Major Player in the Biomarker Clinical Phase Outsourcing - openPR
Drug Discovery Outsourcing Services Market to Achieve a Superb - openPR
Natixis Advisors LLC Lowers Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle - Seeking Alpha
Bioprocess Validation Market to Witness 9.10% CAGR by 2031 | SkyQuest Technology - Benzinga
Thrivent Financial for Lutherans Decreases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Mawer Investment Management Ltd. - MarketBeat
CLSA Downgrades Charles River Laboratories International (NYSE:CRL) to Underperform - MarketBeat
Sumitomo Mitsui Trust Group Inc. Grows Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Mizuho Securities USA LLC Buys 92,895 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
KBC Group NV Has $16.66 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Holdings Decreased by Victory Capital Management Inc. - MarketBeat
Entropy Technologies LP Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Entropy Technologies LP Trims Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Empower Advisory Group LLC Sells 3,497 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Labs to close Skokie office - Crain's Chicago Business
Charles River Laboratories To Present At UBS Global Healthcare Conference; Webcast At 1:15 PM ET - Nasdaq
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by WCM Investment Management LLC - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Position Lowered by Amalgamated Bank - MarketBeat
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024. - Marketscreener.com
Genotoxicity Tests Market Trends Detailed Research and Projected Growth through 2032 - WICZ
Charles River Laboratories to Present at UBS and Jefferies Conferences - sharewise
Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):